Table 1.
Baseline Characteristics of the Study Cohort Prior to Propensity Score Matching
| Total (N = 3,122) | Aspirin (n = 1,124) | No Aspirin (n = 1,998) | P | |
|---|---|---|---|---|
| Age, y | 50.8 ± 9.3 | 52.9 ± 9.3 | 49.7 ± 9.1 | <0.001 |
| Female sex | 1,242 (40) | 430 (38) | 812 (41) | 0.2 |
| Race | <0.001 | |||
| White | 2,333 (75) | 892 (79) | 1,441 (72) | |
| Black | 576 (18) | 172 (15) | 404 (20) | |
| Other | 213 (7) | 60 (5) | 153 (8) | |
| Country | <0.001 | |||
| United States | 2,204 (71) | 830 (74) | 1,374 (69) | |
| Canada | 405 (13) | 101 (9) | 304 (15) | |
| Brazil | 513 (16) | 193 (17) | 320 (16) | |
| High-dose vitamin treatment arm | 1,562 (50) | 543 (48) | 1,019 (51) | 0.2 |
| Low-dose vitamin treatment arm | 1,560 (50) | 581 (52) | 979 (49) | 0.2 |
| Diabetes | 1,101 (35) | 523 (47) | 578 (29) | <0.001 |
| Hypertension | 2,845 (91) | 1,052 (94) | 1,793 (90) | <0.001 |
| Smoking | 0.2 | |||
| Current | 351 (11) | 117 (10) | 234 (12) | |
| Former | 1,142 (37) | 434 (39) | 708 (35) | |
| Never | 1,629 (52) | 573 (51) | 1,056 (53) | |
| Living donor | 1,352 (43) | 481 (43) | 871 (44) | 0.7 |
| CNI-based regimen | 2,769 (89) | 1,012 (90) | 1,757 (88) | 0.08 |
| Sirolimus use | 262 (8) | 108 (10) | 154 (8) | 0.07 |
| Statin use | 1,546 (50) | 623 (55) | 923 (46) | <0.001 |
| Graft vintage, y | 4.1 [1.7–7.5] | 3.3 [1.4–6.7] | 4.4 [1.9–8.2] | <0.001 |
| BMI, kg/m2 | 29.1 ± 6.4 | 29.3 ± 6.3 | 28.9 ± 6.4 | 0.2 |
| Systolic BP, mm Hg | 135.5 ± 19.4 | 136.0 ± 20.0 | 135.3 ± 19.0 | 0.3 |
| Diastolic BP, mm Hg | 79.3 ± 11.9 | 77.8 ± 11.9 | 80.1 ± 11.8 | <0.001 |
| eGFR, mL/min/1.73 m2 | 49.6 ± 18.0 | 50.3 ± 18.1 | 49.2 ± 17.9 | 0.1 |
| eGFR strata | 0.6 | |||
| ≥90 mL/min/1.73 m2 | 97 (3) | 35 (3) | 62 (3) | |
| 60–<90 mL/min/1.73 m2 | 661 (21) | 250 (22) | 411 (21) | |
| 45–<60 mL/min/1.73 m2 | 967 (31) | 354 (31) | 613 (31) | |
| 30–<45 mL/min/1.73 m2 | 1,024 (33) | 362 (32) | 662 (33) | |
| <30 mL/min/1.73 m2 | 373 (12) | 123 (11) | 250 (13) | |
| ACR, mg/g | 24.7 [8.4–95.6] | 19.7 [7.8–64.3] | 27.7 [8.9–113.8] | 0.009 |
| ACR strata | ||||
| <10 mg/g | 915 (29) | 356 (32) | 559 (28) | <0.001 |
| 10–29 mg/g | 804 (26) | 319 (28) | 485 (24) | |
| 30–299 mg/g | 1,017 (33) | 338 (30) | 679 (34) | |
| ≥300 mg/g | 386 (12) | 111 (10) | 275 (14) | |
| Cholesterol | <0.001 | |||
| Total, mg/dL | 186.5 ± 43.1 | 182.3 ± 42.7 | 189.0 ± 43.2 | |
| HDL, mg/dL | 47.0 ± 14.2 | 46.5 ± 13.9 | 47.2 ± 14.4 | 0.2 |
| LDL, mg/dL | 102.4 ± 33.5 | 99.6 ± 32.2 | 104.0 ± 34.0 | <0.001 |
| Triglycerides, mg/dL | 163 [111–235] | 159 [109–230] | 166 [113–236] | 0.08 |
Note: Values for categorical variables are given as number (percentage); values for continuous variables, as mean ± standard deviation or median [interquartile range].
Abbreviations: ACR, albumin-creatinine ratio; BMI, body mass index; BP, blood pressure; CNI, calcineurin inhibitor; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; LDL, low-density lipoprotein.